目的 挖掘FAERS數(shù)據(jù)庫(kù)中替爾泊肽相關(guān)不良事件的風(fēng)險(xiǎn)信號(hào)，全面評(píng)估該藥臨床應(yīng)用的安全性。方法 收集FAERS數(shù)據(jù)庫(kù)中2022年第2季度—2024年第3季度上報(bào)的替爾泊肽的不良事件報(bào)告。采用報(bào)告比值比（ROR）法、貝葉斯置信區(qū)間遞進(jìn)神經(jīng)網(wǎng)絡(luò)（BCPNN）法進(jìn)行數(shù)據(jù)分析，使用國(guó)際醫(yī)學(xué)用語(yǔ)詞典（MedDRA）藥物不良反應(yīng)術(shù)語(yǔ)集中的系統(tǒng)器官分類（SOC）和首選術(shù)語(yǔ)（PT）進(jìn)行規(guī)范漢化及分類統(tǒng)計(jì)。結(jié)果 提取到替爾泊肽為首要懷疑藥物的不良事件報(bào)告47 306例，經(jīng)過(guò)ROR法和BCPNN法進(jìn)行檢測(cè)，排除產(chǎn)品問(wèn)題、各類損傷中毒及操作并發(fā)癥等與藥物無(wú)關(guān)的信號(hào)后最終獲得178個(gè)PT，涉及20個(gè)SOC。PT中包括常見(jiàn)不良事件如注射部位不適、其次為惡心、便秘、胰腺炎等，嚴(yán)重不良事件如甲狀腺癌。還檢測(cè)到血降鈣素升高、皮質(zhì)醇增加、月經(jīng)期出血過(guò)多等說(shuō)明書(shū)未提及的不良事件。此外，使用韋伯分布檢驗(yàn)分析了替爾泊肽不良事件的發(fā)生時(shí)間（TTO），發(fā)現(xiàn)不良事件的中位TTO為28 d，四分位距為7～92 d，大多數(shù)病例發(fā)生在替爾泊肽給藥后30 d內(nèi)（52.44%）。結(jié)論 除了發(fā)現(xiàn)替爾泊肽說(shuō)明書(shū)提及的常見(jiàn)不良反應(yīng)外，還發(fā)現(xiàn)了該藥新的、嚴(yán)重的不良反應(yīng)，有助于替爾泊肽給藥后不良事件的臨床監(jiān)測(cè)和風(fēng)險(xiǎn)識(shí)別，保障臨床安全用藥。

Objective To explore the risk signals of tilposide related adverse events in FEARS database, and comprehensively evaluate the safety of the drug in clinical application. Methods The adverse events reports of tilposide from the second quarter of 2022 to the third quarter of 2024 in FAERS database were collected. The reported odds ratio (ROR) method and Bayesian confidence interval progressive neural network (BCPNN) method were used for data analysis, and the system organ classification (SOC) and preferred term (PT) in the International Dictionary of medical terms (MedDRA) adverse drug reaction terminology set were used for standardized sinicization and classification statistics. Results A total of 47 306 adverse events reports with tilposide as the primary suspected drug were extracted. After ROR method and BCPNN method were used to detect, 178 PTs involving 20 SOC were finally obtained after excluding signals unrelated to the drug, such as product problems, various injuries, poisoning, and operation complications. PT includes common adverse events such as discomfort at the injection site, followed by nausea, constipation, pancreatitis, etc, and serious adverse events: thyroid cancer. Adverse events not mentioned in the instructions were also detected, such as elevated levels of calcitonin, cortisol, and heavy menstrual bleed. In addition, we used Weber distribution test to analyze the occurrence time (TTO) of tilposide ade, and found that the median tto of adverse events was 28 days, and the interquartile range was 7 to 92 days. Most cases occurred within 30 days after tilpotide administration (52.44%). Conclusion In addition to the common adverse reactions mentioned in the instruction manual of tilposide, this study also found new and serious adverse reactions of tilposide, which is helpful for the clinical monitoring and risk identification of ADE after tilposide administration, and ensures the clinical safety of drug use.

R977